Phaseline

Targets › Na+/K+-ATPase

Na+/K+-ATPase: drug programs, companies and trials

7 programs from 7 companies in 7 trials: 3 Phase 2, 3 Phase 1, 1 Phase 4; Cardiovascular, Oncology, Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: the race on Na+/K+-ATPase, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hospital General de Agudos "Dr. Cosme Argerich"Digoxin
Sodium/potassium-transporting ATPase inhibitor
Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2Phase 4Acute Heart Failure (AHF)Dec 2027
H. Lee Moffitt Cancer Center and Research InstituteDigoxin
Sodium/potassium-transporting ATPase inhibitor
Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2Phase 2MedulloblastomaFeb 2027
Seismic Pharmaceuticals Operationsistaroxime
Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator
Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2Phase 2Cardiogenic ShockDec 2028
Yale UniversityDigoxin
Sodium/potassium-transporting ATPase inhibitor
Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2Phase 2NASHJan 2029
Danae Hamouda, MDDigoxin
Sodium/potassium-transporting ATPase inhibitor
Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2Phase 1Advanced Pancreatic CancerDec 2026
State University of New York - Downstate Medical CenterDigoxin
Sodium/potassium-transporting ATPase inhibitor
Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2Phase 1Pancreatic Cancer MetastaticDec 2028
Windtree TherapeuticsIstaroxime
Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator
Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2Phase 1Cardiogenic Shock–

Conditions

Cardiogenic Shock (2) Acute Heart Failure (AHF) (1) Medulloblastoma (1) Advanced Pancreatic Cancer (1) Pancreatic Cancer Metastatic (1) NASH (1)

Modalities

small molecule (7)

Companies

Seismic Pharmaceuticals Operations (1) Hospital General de Agudos "Dr. Cosme Argerich" (1) Windtree Therapeutics (1) H. Lee Moffitt Cancer Center and Research Institute (1) Danae Hamouda, MD (1) State University of New York - Downstate Medical Center (1) Yale University (1)

Related targets

ATP1B2 (7) ATP1B1 (7) ATP1B3 (7) FXYD2 (7)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.